Please enter the email address you used to register, then we will send you a link to choose a new password
Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer the...
A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patie...
Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the pric...